Elsevier

Cytokine

Volume 129, May 2020, 155048
Cytokine

Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma

https://doi.org/10.1016/j.cyto.2020.155048Get rights and content

Highlights

  • DLBCL is a heterogeneous group of lymphomas.

  • Secondary CNS involvement of DLBCL carries poor outcomes.

  • To predict secondary CNS involvement, we analyzed serum level of cytokines.

  • Positive IL-10 was associated with shorter time to the secondary CNS event.

Abstract

Background

As diffuse large B-cell lymphoma (DLBCL) is a very heterogeneous group of lymphomas, much effort has gone in trying to identify patients with increased risk for early death or secondary central nervous system (CNS) involvement. To better predict their outcomes, we measured the levels of various cytokines in serum samples of patients with DLBCL and analyzed their clinical outcomes.

Methods

We measured the levels of seven serum cytokines at diagnosis in 313 DLBCL patients who were treated with R-CHOP. Their impact on clinical outcomes, including time to secondary CNS involvement and the 3-year overall survival (OS) rate, were analyzed.

Results

The median age was 56 years (range, 16–86 years), and 177 patients (57%) were men. Secondary CNS involvement was found in 5.4% (16/294) cases, and time to secondary CNS involvement was significantly short in patients with elevated interleukin (IL)-10 (p = 0.012). With the 3-year OS rate of the whole cohort being 73.6%, serum levels of several cytokines, such as CCL3 > 4.0 pg/mL (54.3% vs. 76.1%, p = 0.001), CCL5 > 450 pg/mL (57.0% vs. 78.1%, p < 0.001), any expression of IL-6 (59.3% vs. 76.6%, p = 0.001), and any expression of IL-10 (68.2% vs. 84.5%, p = 0.001), showed prognostic impact. Higher expressions of these cytokines were associated with worse manifestations of clinical prognostic factors.

Conclusions

Our study revealed that some cytokines impact OS and secondary CNS involvement. Future studies are required to elucidate how these findings can be incorporated to the conventional prognostic factors for more tailored approaches.

Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common, aggressive non-Hodgkin lymphoma accounting for 30–40% of cases worldwide [1]. The treatment outcome of patients with DLBCL has significantly improved since the introduction of rituximab in combination with the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) [2], [3]. However, more than 30% of patients still experience relapse even after they achieve a complete response, and they ultimately have a poor prognosis [4], [5]. In particular, central nervous system (CNS) relapse carries poor outcomes in most patients; however, secondary CNS involvement is a relatively uncommon event occurring in around 5% of DLBCL patients [6], [7], [8]. Thus, appropriate CNS prophylaxis should be performed in highly selected patients. However, the identification of high-risk patients for CNS relapse still remains controversial. In the past, clinical risk models, such as the International Prognostic Index (IPI), and the involvement of certain sites, such as the paranasal sinus, testis, and retroperitoneal lymph nodes, were considered to indicate a higher risk of secondary CNS involvement [9], [10], [11], [12]. Currently, the CNS-IPI model combining five IPI factors with kidney or adrenal gland involvement is recommended as a risk model to help identify high-risk patients for CNS relapse [13]. However, clinical risk models have limitations because their parameters may not reflect all aspects of biological aggressiveness. As our understanding of the molecular pathogenesis of DLBCL has advanced, high-grade B-cell lymphoma with translocations of MYC and BCL2 and/or BCL6, also known as double- or triple-hit lymphoma, has been considered a risk factor for CNS relapse [14], [15]. However, this may not be sufficient for predicting CNS relapse because these patients only account for about 5% of DLBCL, and not all patients have CNS relapse.

Cytokines and chemokines are involved in normal homeostasis, such as inflammation and wound healing; however, chemokines are also involved in tumor cell migration, contributing to tumor cell proliferation and survival [16], [17]. In addition, their role in tumor growth and metastasis has been demonstrated in various malignancies, including lymphomas [18]. For instance, interleukin-6 and -10 (IL-6, IL-10) in cerebrospinal fluid (CSF) reportedly have a role in the diagnosis of primary CNS lymphoma [19]. Considering that IL-6 and IL-10 are major cytokines related with the JAK/STAT pathway, which plays a role in tumor growth of DLBCL, the serum levels of IL-6 and IL-10 may represent the likelihood of secondary CNS involvement and risk of CNS relapse. Indeed, elevated serum levels of IL-10 were closely associated with JAK2 activation and MYC and Bcl-2 expression in DLBCL [20]. Chemokine (C-C motif) ligand 3 (CCL3), a pro-inflammatory chemokine produced by many cells such as macrophages and lymphocytes, is also known to be produced by lymphoma cells, and CCL3 can attract accessory cells to the tissue microenvironment in response to B cell receptor (BCR) signaling, which is an important pathway in DLBCL [21], [22]. Constitutive elevation of serum chemokine (C-C motif) ligand 5 (CCL5) was associated with immune evasion of lymphoma cell-lines [23]. TNF-α (tumor necrosis factor-α) is an important pro-inflammatory cytokine that plays a central role in immune responses and acts as an inducer of IL-10 secretion in vitro [24]. The elevated plasma level of this cytokine adversely impacted outcomes of Hodgkin’s lymphoma patients [25]. However, data about the impact of these cytokines on the secondary CNS involvement of DLBCL are lacking. Therefore, we analyzed the association of pretreatment serum cytokines and chemokines with the occurrence of CNS relapse in DLBCL patients who had serum samples available for study to analyze their role in predicting the occurrence of CNS relapse.

Section snippets

Patients

We retrospectively analyzed the clinical data of DLBCL patients (n = 313) who were enrolled in a prospective cohort study between September 2008 and December 2011 (NCT#00822731). All patients were newly diagnosed as having DLBCL according to the 2008 World Health Organization classification [26]. Patients who had archived serum samples available for analysis were analyzed, and primary CNS lymphoma was excluded. We analyzed the recorded data of the cohort study including information at the time

Patient characteristics & clinical outcomes

The median age of 313 patients was 56 years (range, 16–86 years), and 177 patients (57%) were men. Most patients were in good performance status, with 261 patients (83%) in ECOG PS 0–1 and 52 (17%) in ECOG PS 2–4. Overall, 159 patients (51%) had localized disease with Ann Arbor stage I/II, whereas 154 patients (49%) had stage III/IV; 107 patients (34%) showed involvement of ≥2 extranodal sites, and increased serum LDH was detected in 169 patients (45%). Accordingly, 144 (46%), 59 (19%), 51

Discussion

Secondary CNS involvement has long remained a concerning issue in the management of DLBCL patients because CNS relapse carries nearly universally poor outcomes [28], [29]. Furthermore, once patients show CNS relapse or progression during or after treatment, systemic disease progression usually occurs following CNS involvement. Considering that CNS involvement is usually an exclusion criterion for participation in clinical trials of novel agents, it is of critical importance to identify patients

CRediT authorship contribution statement

Jun Ho Yi: Conceptualization, Formal analysis, Data curation, Writing - original draft. Yoon Sang Eun: Conceptualization, Investigation, Data curation. Kyung Ju Ryu: Conceptualization, Investigation. Young Hyeh Ko: Conceptualization. Won Seog Kim: Conceptualization, Resources, Writing - review & editing, Supervision. Seok Jin Kim: Conceptualization, Methodology, Resources, Writing - review & editing, Supervision.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We thank all our colleagues for participating in the research and express our gratitude to the 20-20 project of Samsung Medical Center and the National Research Foundation of Korea (NRF-2017R1A2B4005136).

References (52)

  • N. Schmitz et al.

    CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group

    Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol.

    (2012)
  • J.L. Rubenstein et al.

    CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma

    Blood

    (2013)
  • J.G. Taylor et al.

    Microenvironment abnormalities and lymphomagenesis: immunological aspects

    Seminars Cancer Biol.

    (2015)
  • L. Li et al.

    B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma

    Blood

    (2018)
  • H. Qiu et al.

    MYD88 L265P mutation promoted malignant B cell resistance against T cell-mediated cytotoxicity via upregulating the IL-10/STAT3 cascade

    Int. Immunopharmacol.

    (2018)
  • R.A. Wilcox et al.

    Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells

    Blood

    (2009)
  • I. Dlouhy et al.

    High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma

    Leukemia Res.

    (2017)
  • P.J. Jost et al.

    Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications

    Blood

    (2007)
  • B. Coiffier et al.

    CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

    New Engl. J. Med.

    (2002)
  • C. Gisselbrecht et al.

    Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

    J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol.

    (2010)
  • L.J. Costa et al.

    Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation

    Bone Marrow Transplant.

    (2008)
  • N. Schmitz et al.

    CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP

    J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol.

    (2016)
  • S.J. Kim et al.

    Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma

    Ann. Hematol.

    (2011)
  • C.D. Fletcher et al.

    Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era

    Leukemia & Lymphoma

    (2014)
  • J. Zhang et al.

    Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis

    Leukemia Lymphoma

    (2014)
  • S.J. Kim et al.

    Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: results of a multicenter prospective cohort study

    Oncotarget

    (2016)
  • Cited by (0)

    1

    Both authors contributed equally to this article.

    View full text